Does Harvard Pilgrim Health Care Cover Viagra?

How Harvard Pilgrim Formularies Work for ED Drugs

Harvard Pilgrim Health Care operates several distinct plan types, including fully insured commercial plans, self-funded employer plans administered by Harvard Pilgrim, and Medicare Advantage products. Each of those plan types carries its own drug formulary, and formularies are updated at least annually. Sildenafil's tier placement therefore varies by contract year and by employer group.

On the 2024 Harvard Pilgrim commercial formulary, generic sildenafil citrate typically appears at Tier 2 (preferred generic) or Tier 3 (non-preferred brand or specialty generic). Brand-name Viagra, which Pfizer still manufactures, generally lands at Tier 3 or Tier 4 due to its substantially higher acquisition cost. A Tier 3 placement under a standard commercial plan often means a copay of $40 to $70 per fill, though employer contracts can shift that number in either direction.

Erectile dysfunction as a stand-alone diagnosis has historically occupied a gray zone in insurance coverage. The FDA approved sildenafil for pulmonary arterial hypertension (PAH) under the brand name Revatio in 2005, and that indication is covered far more consistently across all plan types because PAH is a life-threatening cardiopulmonary disease [1]. When sildenafil is prescribed specifically for ED, coverage depends on whether the employer sponsor has opted into or out of coverage for "lifestyle drugs," a category defined inconsistently across payers.

Self-funded employers bear the full cost of claims, so they can and do exclude ED medications entirely from their benefit design. If your Harvard Pilgrim card is through a self-funded employer, the employer, not Harvard Pilgrim, controls whether Viagra appears on your formulary at all.

To confirm your specific plan's coverage before filling a prescription, call the member services number on the back of your Harvard Pilgrim ID card or log in to the member portal and use the drug cost estimator tool. The plan's Summary of Benefits and Coverage document, which your employer must provide under the Affordable Care Act, will list whether "sexual dysfunction medications" are excluded.

The Pharmacology Behind Why Sildenafil Costs So Much Less as a Generic

Pfizer's patent on sildenafil for ED expired in the United States in December 2017. Since then, more than a dozen manufacturers have received FDA approval to market generic sildenafil citrate, and retail prices dropped by more than 95% within 18 months of patent expiry [2]. This price collapse is directly relevant to your out-of-pocket cost whether or not Harvard Pilgrim covers the drug.

Sildenafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class. It works by blocking PDE5 in penile smooth muscle, which prevents breakdown of cyclic guanosine monophosphate (cGMP) and prolongs smooth-muscle relaxation in response to sexual stimulation. The FDA's prescribing information for sildenafil describes the onset of action as 30 to 60 minutes, with a plasma half-life of approximately 3 to 5 hours [3]. Tadalafil (Cialis) has a half-life of 17.5 hours, which is why it is sometimes described as the "weekend pill."

The clinical non-inferiority between brand Viagra and generic sildenafil is well-established. A 2020 Cochrane review of PDE5 inhibitors for ED (N=234 trials, N=32,862 participants) found sildenafil significantly improved erectile function scores versus placebo, with a mean IIEF score increase of 8.0 points (95% CI: 7.0 to 9.0) [4]. Brand versus generic comparisons show equivalent bioavailability under FDA's AB-rated substitution standards, meaning the generic is therapeutically interchangeable [5].

The practical implication is this: even if Harvard Pilgrim does not cover brand Viagra on your specific plan, generic sildenafil 20 mg tablets (three tablets taken together to approximate a 60 mg ED dose) may cost $10 to $30 per month through GoodRx or a pharmacy discount program, sometimes less than your plan's copay for a covered drug.

Prior Authorization Requirements for Viagra at Harvard Pilgrim

Prior authorization (PA) for sildenafil at Harvard Pilgrim, when required, typically asks a prescriber to document two things: a confirmed diagnosis of ED with clinical documentation, and either a trial of a lower-cost alternative or a clinical reason why the specific agent requested is medically necessary. The PA process under most Harvard Pilgrim commercial plans runs 3 to 5 business days for standard requests and 24 to 72 hours for urgent requests under the plan's utilization management policy, which aligns with the ACA's requirement that insurers establish an expedited appeals process for urgent care [6].

The American Urological Association's 2018 guideline on ED, reaffirmed in 2024, states: "PDE5 inhibitors are the first-line treatment for erectile dysfunction in most men and should be offered before more invasive therapies are considered" [7]. That guideline language supports a PA request by establishing medical necessity at the class level.

If Harvard Pilgrim denies a PA for sildenafil, the denial letter must include the clinical rationale and must explain your right to appeal. Under Massachusetts state law (226 CMR 15.00), insurers must complete a standard internal appeal within 30 days and an expedited appeal within 72 hours. If the internal appeal fails, members can request an external review through the Massachusetts Division of Insurance, which assigns the case to an independent review organization (IRO) [8].

A prescriber-written letter of medical necessity documenting the patient's cardiovascular workup, psychosocial history, failed non-pharmacologic interventions, and the specific reason sildenafil is preferred over tadalafil or avanafil increases the likelihood of PA approval. Testosterone deficiency, for instance, is a reversible cause of ED found in 10% to 30% of men with the condition [9], and documenting that testosterone has been assessed (and treated if low) strengthens the clinical record supporting PA.

What Harvard Pilgrim Medicare Advantage Plans Cover for ED

Medicare Advantage plans sold by Harvard Pilgrim follow the same federal exclusion that applies to original Medicare. Under 42 U.S.C. § 1395w-102(e), Part D plans are prohibited from covering drugs whose sole indication at the time of approval was for the treatment of sexual dysfunction or infertility. Sildenafil for ED falls squarely into that exclusion [10].

Sildenafil prescribed for pulmonary arterial hypertension under the brand name Revatio is a different story. PAH is not a sexually transmitted or lifestyle-related condition, and Part D plans cover Revatio or generic sildenafil for PAH consistently. The prescriber must use diagnosis code I27.0 (primary pulmonary hypertension) or I27.20 (pulmonary hypertension, unspecified) on the prescription routing, not an ED diagnosis code, for the claim to process [11].

For Medicare-enrolled men who want sildenafil for ED, the realistic options are: paying cash (generic sildenafil runs $10 to $30/month as noted above), using a manufacturer savings card if commercially insured and under 65, or discussing whether a compounded sildenafil-tadalafil formulation from a 503A-accredited pharmacy may offer cost savings. Compounded medications are not FDA-approved products, and the agency has warned about quality variability [12], so that route requires careful prescriber oversight.

Covered Alternatives: Tadalafil, Vardenafil, and Avanafil on Harvard Pilgrim Plans

Because the four approved PDE5 inhibitors are therapeutically similar in efficacy for most men, Harvard Pilgrim formularies occasionally prefer one agent over another on the basis of contracted drug pricing. Tadalafil (generic Cialis) frequently receives Tier 2 preferred generic status on plans that place sildenafil at Tier 3, simply because manufacturer rebates shifted the net cost calculation for the plan sponsor.

The 2020 Cochrane review cited above found that tadalafil and sildenafil produced statistically similar improvements in IIEF scores, with no clinically meaningful difference in efficacy between agents for most men [4]. The AUA guideline makes no preference between approved PDE5 inhibitors and recommends choice based on patient preference regarding onset, duration, and side-effect profile [7].

Avanafil (Stendra), approved by the FDA in April 2012, has a faster onset (as early as 15 minutes in some patients) because it is more selective for PDE5 over PDE6 and PDE11, reducing visual side effects and myalgia [13]. It remains brand-only (no generic as of 2025) and typically appears on Tier 4 of Harvard Pilgrim formularies, making it the most expensive PDE5 option under most plan designs.

Vardenafil (Levitra) has generic availability since 2018. Its pharmacokinetic profile is similar to sildenafil, with a half-life of 4 to 5 hours [14]. It may appear at Tier 2 on select Harvard Pilgrim employer plans where the plan sponsor has negotiated preferred status.

To find which PDE5 inhibitor is covered at the lowest tier on your specific Harvard Pilgrim plan, use the plan's online formulary search tool, enter each drug name individually, and compare estimated member cost-share for a 30-day supply. Doing that comparison before your prescriber sends the prescription to the pharmacy avoids a surprise at the counter.

When ED Is a Symptom of an Insured Underlying Condition

Insurance coverage logic shifts meaningfully when ED is the presenting symptom of a covered underlying condition rather than a primary diagnosis. Conditions that cause ED and that are covered without restriction under virtually all commercial plans include type 2 diabetes, hypogonadism (low testosterone), cardiovascular disease, Peyronie's disease, and neurological disorders such as multiple sclerosis [15].

A 2021 JAMA Network Open study (N=2,232 men) found that 52.4% of men with newly diagnosed ED had at least one previously undiagnosed cardiovascular risk factor identified during their ED workup [16]. That finding supports the practice of a thorough metabolic and hormonal workup before attributing ED purely to psychological or lifestyle causes.

The FDA-approved prescribing information for sildenafil specifically notes that the drug is contraindicated with organic nitrates because the combination may produce severe hypotension [3]. Before prescribing sildenafil, a clinician must assess cardiovascular status, and that cardiovascular evaluation is itself a billable, covered service under Harvard Pilgrim plans. The laboratory workup, which should include fasting glucose, HbA1c, a lipid panel, total testosterone, free testosterone, LH, FSH, and prolactin per Endocrine Society guidance [17], is covered under diagnostic laboratory benefits.

Treating the underlying condition can sometimes resolve ED without a PDE5 inhibitor at all. A 2014 NEJM study (N=305 men with type 2 diabetes and ED) found that intensive lifestyle intervention producing greater than 10% weight loss restored erectile function in 29% of participants without any pharmacotherapy [18]. That is a meaningful number for men who want to avoid a monthly prescription cost regardless of coverage.

How to Get Your Harvard Pilgrim Prescription Approved: A Step-by-Step Process

Step one: confirm formulary status. Log in at harvardpilgrim.org, manage to "Drug Cost Estimator," and search sildenafil and its alternatives. Note the tier and whether PA is indicated.

Step two: schedule a clinical visit. A telemedicine visit qualifies for this under most Harvard Pilgrim plans post-2020. The prescriber should document an IIEF-5 score (scores of 1 to 21 indicate ED, with 1 to 7 classified as severe), the duration of symptoms, the presence of morning erections, and relevant comorbidities [19].

Step three: complete the hormonal and metabolic workup. Total testosterone below 300 ng/dL is the threshold for hypogonadism per the Endocrine Society's 2018 guideline, and treatment of hypogonadism may itself improve ED [17]. Document these results in the medical record before submitting a PA.

Step four: if PA is required, ask your prescriber to submit it with the AUA guideline language quoted above, the IIEF-5 score, and the relevant diagnosis codes (N52.9 for male erectile dysfunction, unspecified, or N52.01 for erectile dysfunction due to arterial insufficiency).

Step five: if denied, appeal. Request the plan's clinical criteria document, compare the denial rationale to the AUA guideline, and submit a written appeal with a letter of medical necessity that cites the guideline directly.

Step six: use a discount card if appeal fails. GoodRx, RxSaver, and similar programs are accepted at most Harvard Pilgrim network pharmacies. Sildenafil 100 mg tablets (which can be split into two 50 mg doses, halving cost) are available at major retail pharmacies for approximately $15 to $25 for a 6-tablet supply using discount pricing, regardless of insurance status.

Cardiovascular Safety Considerations Harvard Pilgrim Clinicians Review

No discussion of PDE5 inhibitor coverage is clinically complete without addressing cardiac risk. The Princeton Consensus Conference III (2012) stratified men into low, intermediate, and high cardiovascular risk categories for sexual activity and PDE5 inhibitor use [20]. Low-risk men with stable coronary artery disease, controlled hypertension on fewer than three medications, and no recent cardiac events can receive sildenafil with minimal additional workup. High-risk men, including those with unstable angina or recent MI within 2 weeks, should defer sexual activity and PDE5 inhibitor use until stabilized.

Harvard Pilgrim prior authorization forms for sildenafil frequently ask about nitrate use precisely because of this interaction. A prescriber who answers "yes" to current nitrate use will receive a denial on pharmacological safety grounds, not coverage policy grounds, and that distinction matters for appeals.

The drug interaction between sildenafil and alpha-blockers is also clinically significant. Concomitant use may cause symptomatic hypotension, particularly with doxazosin. The FDA label recommends initiating sildenafil at 25 mg in men already stabilized on alpha-blocker therapy [3]. Tamsulosin has a more uroselective profile and carries lower hypotension risk with sildenafil, making it the preferred alpha-blocker in men who also need ED pharmacotherapy [21].

What the Evidence Says About Long-Term ED Treatment Adherence

One factor that affects coverage decisions at the plan level is adherence. Men who fill PDE5 inhibitor prescriptions discontinue them at higher rates than most other chronic medications. A 2019 Journal of Sexual Medicine study (N=4,478 men) found that 48% of men who filled an initial PDE5 inhibitor prescription did not fill a second prescription within 12 months, with cost cited as the primary reason in 34% of non-refills [22].

Generic sildenafil's dramatic cost reduction has improved adherence metrics. The same study found a 22-percentage-point improvement in 12-month refill rates after generic sildenafil became widely available in 2018, which has cost implications for plans tracking total ED-related healthcare utilization.

The Endocrine Society's clinical practice guideline on male hypogonadism notes that treating testosterone deficiency with testosterone replacement therapy (TRT) in hypogonadal men with ED improves PDE5 inhibitor response in men who were previously non-responders [17]. This has a direct formulary implication: a man on Harvard Pilgrim whose sildenafil is not producing adequate response may benefit from a testosterone level check before dose escalation, and TRT is covered under most commercial Harvard Pilgrim plans under standard endocrinology benefits.